Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None20222021202020192018201720162015 Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit 09/06/2017 Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting 06/05/2017 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting 04/04/2017 Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs 01/03/2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting 12/05/2016 Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting 11/03/2016 Poseida Therapeutics Establishes Scientific Advisory Board 09/08/2016 Poseida Therapeutics Expands Executive Leadership Team 08/18/2016 Poseida Therapeutics Announces Series A Financing 12/16/2015 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Next page next › Last page last » Displaying 71 - 80 of 84
Year None20222021202020192018201720162015 Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit 09/06/2017 Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting 06/05/2017 Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting 04/04/2017 Poseida Therapeutics Appoints Debra Gessner as Vice President, Regulatory Affairs 01/03/2017 Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting 12/05/2016 Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting 11/03/2016 Poseida Therapeutics Establishes Scientific Advisory Board 09/08/2016 Poseida Therapeutics Expands Executive Leadership Team 08/18/2016 Poseida Therapeutics Announces Series A Financing 12/16/2015 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Next page next › Last page last » Displaying 71 - 80 of 84
Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting 06/05/2017
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy 05/22/2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual Meeting 04/04/2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual Meeting 12/05/2016
Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual Meeting 11/03/2016